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Introduction 
Despite provisions made by the 2010 Affordable Care Act to 
expand Medicaid and make health insurance more available, 
many low-income individuals remain uninsured or 
underinsured.1,2 Lack of insurance can be a barrier to 
receiving needed healthcare.1 Chronic respiratory diseases, 
such as asthma and chronic obstructive pulmonary disease 
(COPD), disproportionately impact people with low incomes, 
with factors such as smoking or exposure to secondhand 
smoke, air pollution, and occupational dust and chemicals 
increasing the risk of disease.3,4 A variety of breathing 
medications exist to control these diseases and manage 
symptoms, such as oral and inhaled bronchodilators, oral and 
inhaled corticosteroids, as well as leukotriene receptor 
antagonists and selective phosphodiesterase-4 inhibitors. 
However, prescription cost can be a major financial burden 
for patients without adequate insurance coverage.2    
 
A study examining cost-related medication nonadherence in 
Medicare beneficiaries by Castaldi et al. (2010) found that 
patients paying more than twenty dollars per month for 
inhalers were at a significantly higher risk for cost-related 
nonadherence compared to those who had no out-of-pocket 
inhaler costs.5 Nonadherence to breathing medications can 
lead to uncontrolled respiratory disease, which may result in 
expensive emergency department (ED) visits and 
hospitalizations.  A retrospective cohort study by Hasegawa et 
al. (2014) found that lower socioeconomic status was 
significantly associated with a higher frequency of ED visits 
for acute exacerbation of COPD.6 Similarly, a cross-sectional 
study of outpatient asthma-related ED visits by Wang et al. 
(2014) identified that the majority of patients in their sample 
were low-income, defined as ≤ 200% of the federal poverty 
level.7 Prescription-related issues after hospital discharge, 
most often not filling discharge prescriptions, have been 
found to be especially common among patients with 
Medicare HMO coverage, Medicaid, or no insurance, and in 
patients prescribed an inhaler.8   
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A patient’s medication plan should be developed based on his 
or her access to resources and consideration of the cost of 
the medications and interventions.9 According to a physician 
survey by Reichert et al. (2000), while most prescribers 
recognize that medication cost is important, few have easy 
access to drug cost information and even fewer have received 
formal training about the cost of medications.10 Prescribing 
clinicians should consider cost information when selecting 
potential breathing medications so that the most affordable  
drug is prescribed to best meet the patient’s therapeutic 
goals. 
 
Pharmacists can promote utilization of assistance programs 
for patients who are uninsured and underinsured. These 
patients may include those who exceed Medicaid coverage or 
for whom Medicaid coverage is pending, those without any 
health insurance or without a prescription drug benefit, those 
for whom the planned drug therapy is not covered by 
insurance or covered inadequately (copay not affordable), 
and those enrolled in charity programs.11  However, in our 
experience, even pharmacists who work with the 
underserved daily may struggle to provide breathing 
medications due to the lack of consistency in the types of 
assistance programs available for each breathing medication, 
as well as specific patient qualifications that impact a 
patient’s eligibility to receive medications through these 
routes. The challenge of breathing medication access for the 
uninsured and underinsured needs to be characterized so 
that key stakeholders, such as prescribers and payers, can 
understand the magnitude of the issue and the options for 
improved breathing medication access. 
 
Purpose. The purpose of this study was to explore access to 
breathing medications in an uninsured and underinsured 
patient population and identify needs related to additional 
medication access resources. Specific aims included 
describing the population of patients who are relying on a 
charitable pharmacy to provide access to breathing 
medications, identifying methods utilized by a charitable 
pharmacy to provide breathing medications, and describing 
individual patient experiences with their respiratory health.   
 
Setting. At the Charitable Pharmacy of Central Ohio, we 
provide medications at no charge for patients in Franklin 
County who are at or below 200% of the federal poverty level 
and are either uninsured or underinsured. Patients are 
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considered underinsured if they meet financial eligibility and 
have insurance but cannot afford their medications despite 
insurance coverage. We utilize several access routes to 
provide medications to our patients including manufacturer 
bulk-replenishment programs, drug repositories, charitable 
distributors, and purchase with our own pharmacy funds. 
Table 1 contains descriptions and comparisons of each access 
route utilized by our charitable pharmacy. Despite having 
multiple resources available for our underserved patients, we 
still struggle to consistently provide some medications to our 
patients, particularly breathing medications. Inhalers are 
especially costly, which can result in patients going to the ED 
for care and potentially suffering from poor quality of life due 
to uncontrolled breathing conditions. 
 
Methods 
This was a descriptive study approved by the Ohio State 
University Institutional Review Board that used a sequential, 
exploratory design. In order to describe access issues for 
uninsured and underinsured patients who require breathing 
medications, we collected quantitative data from a 
retrospective records review (Phase I) and then summarized 
individual patient experiences with breathing medications 
and respiratory health (Phase II).    
 
Phase I. In Phase I, a dispensing report utilizing our dispensing 
software system (QS/1®) was generated to identify patients 
who filled medications at the Charitable Pharmacy of Central 
Ohio during the three-month time period between December 
11, 2014 and March 11, 2015. Patients who filled breathing 
medications during this time were separated out for further 
analysis. Quantitative data was collected from the dispensing 
report, financial database, and medical records review for 
these patients. Objective data gathered from the dispensing 
report included number and types of breathing medications 
prescribed, routes from which breathing medications were 
obtained, and number of prescribers for breathing 
medications. Data collected from the financial database and 
medical records review included patient demographics, 
respiratory diagnoses, and issues detailed in patient charts 
related to access to prescribed breathing medications.   
 
Phase II. In Phase II, patients were telephoned by a study 
investigator and invited to participate in a patient interview 
to share their experiences about obtaining breathing 
medications and their respiratory health. They were offered a 
$10 grocery store gift card incentive to participate in the 
interview either in-person or via telephone. Patients verbally 
consented to participate in a semi-structured interview which 
gathered information including respiratory disease history, 
payer situation, perception of respiratory health, 
modifications to breathing regimens (both provider-initiated 
and patient-initiated), and any ongoing access issues with 
breathing medications. Appendix A contains specific 
interview questions utilized during the interview. Interviews 
were audio-recorded, transcribed by a third party, and 
analyzed by investigators to determine themes. These 
themes were determined by identifying common experiences 
between all or most patients and patients’ experiences with 
breathing medication access.   
 
Statistical Analysis. Analyses were performed in SAS version 
9.2 (SAS institute, Cary, NC). The study was exploratory in 
nature and not powered to detect specific differences; no 
formal hypothesis testing was conducted. All demographic 
and interview data was summarized using descriptive 
statistics. Categorical variables were expressed using 
frequencies and percentages. Continuous variables were 
expressed using means and standard deviations.   
 
Results 
Phase I. Overall, 777 patients filled a prescription during the 
study period, and 181 (23.3%) of those patients filled a 
breathing medication totaling 494 breathing medications 
dispensed. The majority of patients with documented race 
were African American (n=90, 52.9%) and Caucasian (n=69, 
40.6%). The most common respiratory diagnoses were 
asthma (n=75, 41.4%) and COPD (n=65, 35.9%). Detailed 
demographic data is displayed in Table 2.    
 
Most patients were prescribed an “as needed” breathing 
medication (n=151, 83.4%), while nearly half were prescribed 
a “controller” medication (n=88, 48.6%). Examples of “as 
needed” and “controller” breathing medications are shown in 
Table 3. Medications were obtained through purchase 
(41.1%), manufacturer bulk-replenishment (38.5%), 
repository (10.5%), and a charitable medication distributor 
(9.9%). A total of 50 patients (27.6%) reported utilizing routes 
in addition to the charitable pharmacy to access their 
breathing medications within the past year. Figure 1 conveys 
per-patient data regarding number of breathing medications 
dispensed, access routes utilized, and number of prescribers 
of breathing medications.   
 
Phase II. Five patients verbally consented to and completed a 
semi-structured interview regarding their experience with 
breathing medication access and respiratory health. Each 
patient had a different prescription insurance status, 
including uninsured (n=1), Medicare with Part D coverage 
(n=1), Medicare without Part D coverage (n=1), Medicaid 
(n=1), and private insurance (n=1). Analysis of transcribed 
interviews revealed common themes. All patients (n=5) 
reported poor perception of respiratory health, history of ED 
visits or hospitalizations due to uncontrolled respiratory 
disease that decreased in frequency after receiving breathing 
medications from the charitable pharmacy, and incorrect use 
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of inhalers to extend their duration of use. All patients 
(except n=1 insured by Medicaid) reported going without 
breathing medications for some period of time prior to 
coming to the charitable pharmacy. Additionally, all patients 
(except n=1 insured by Medicare with Part D coverage) 
reported that the charitable pharmacy had to request a 
medication change due to access issues or was unable to 
obtain the prescribed breathing medication. Table 4 contains 
patient case summaries. 
 
Discussion 
This descriptive research study identified characteristics of 
patients who are relying on a charitable pharmacy to provide 
their breathing medications, and summarized themes 
regarding the challenges and consequences patients have 
faced while struggling to obtain prescribed breathing 
medications.   
 
We found that respiratory disease is particularly common in 
our patient population, with almost a quarter of our total 
pharmacy population filling a breathing medication during 
the study period. The prevalence of respiratory disease in our 
charitable pharmacy appears to be high compared to the 
prevalence generally reported in the United States. According 
to a 2013 National Health Interview Survey, 7% of adults in 
the United States have asthma, while we found that 12.7% 
(n=99) of our total pharmacy population has either asthma or 
a combination of asthma and COPD.12 A 2011 Behavior Risk 
Factor Surveillance System identified 7.1-9.3% of adults in 
Ohio as having COPD, while 11.5% (n=89) of our total 
pharmacy population has COPD or a combination of asthma 
and COPD.13 The increased prevalence of respiratory disease 
in our population may be due to asthma and COPD 
disproportionately affecting people of low socioeconomic 
status.3,14 Our pharmacy population’s prevalence of 
respiratory disease aligns with that identified by the Kaiser 
Commission, which found that 23% of Medicaid beneficiaries 
have a chronic respiratory illness according to 2009 Medicaid 
Expenditure Panel Survey data.3 While only a small 
percentage of our patients who filled breathing medications 
were Medicaid beneficiaries, the prevalence data provided by 
the Kaiser Foundation may be considered a relevant 
comparison due to the low-income status of the patients 
utilizing the charitable pharmacy.   
 
Another reason we may have observed a higher prevalence of 
patients with respiratory disease at our charitable pharmacy 
is because breathing medications are often expensive 
compared to many medications for other chronic conditions. 
Effective December 31, 2008, the US Food and Drug 
Administration banned the use of chlorofluorocarbon (CFC) 
albuterol inhalers due to environmental harm through ozone-
depletion.15,16 This act prompted the production of new 
inhaler designs with new patents and higher costs.16 
Currently, there are no generic inhalers in the United States.  
The high cost of breathing medications may be driving our 
low-income patients with breathing conditions to seek 
medication assistance.   
 
While patients included in this study were able to fill at least 
one breathing medication through the charitable pharmacy, 
our findings suggest several medication access challenges 
remain. The charitable pharmacy utilized bulk-replenishment 
programs, drug repository, and a charitable medication 
distributor for access. However, 41% of all breathing 
medications dispensed during the study period had to be 
purchased by the charitable pharmacy. The charitable 
pharmacy will only purchase medications as a last resort if 
the medications are not available through any other access 
route. Since most community pharmacies do not have the 
resources of the charitable pharmacy, 41% of the inhalers we 
dispensed may have otherwise been unobtainable for our 
patients had they filled their prescriptions elsewhere. 
 
Further investigation revealed that the charitable pharmacy 
had to utilize two or more access routes for nearly one-third 
of its patients in order to obtain prescribed breathing 
medications. Reasons for using more than one route may be 
due to route-specific drug availability or patient eligibility 
issues (see Table 1).  For example, a patient underinsured 
with prescription insurance would only be eligible for 
repository drugs or drugs purchased by the charitable 
pharmacy, thus limiting resources available to him/her. 
Uninsured patients are eligible to receive medications 
through a larger number of access routes, but the issue of 
drug availability remains. Bulk-replenishment programs, for 
example, only provide certain brand-name medications. If 
there is not a manufacturer assistance program for a 
particular inhaler, a patient must wait for the medication to 
be donated to the charitable distributor or rely on financial 
availability for the medication to be purchased through the 
charitable pharmacy’s operating budget. These limitations 
make navigating available medication access routes 
particularly challenging. 
 
In cases where the prescribed breathing medication was not 
available through any access route, the charitable pharmacy 
requested therapeutic substitution from physicians when 
possible via telephone or fax communication.  One of the 
interviewees shared that the charitable pharmacy had to not 
only request an alternative inhaler which was more readily 
available, but also a nebulizer because the necessary class of 
breathing medications was most affordable through a 
nebulized solution formulation. Another interviewee shared 
that he/she had to go without his/her inhaled breathing 
medication on several occasions because the physician was 
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unwilling to accept the therapeutic alternative recommended 
by the pharmacist. Our data indicated that the majority of 
patients had only one physician writing prescriptions for the 
patient’s breathing medications, so education opportunities 
about cost and access may be manageable. It is important 
that health care professionals be cognizant of medication 
costs and access, particularly if the prescribed breathing 
medications are financially unobtainable for their patients.   
 
The medical records review showed that 27.6% of patients 
filling breathing medications used a resource in addition to 
the charitable pharmacy to obtain their breathing 
medications within the last year. Alternative resources might 
include EDs, drug samples through physician offices, 
medication assistance programs, 340b drug pricing, or retail 
purchase (with or without insurance) at community 
pharmacies. In the case of retail purchase, the interviewees 
were asked how much money they would be able to spend 
per month on breathing medications. Answers ranged from 
being able to pay very little for their breathing medications to 
fifty dollars per month (see Table 4). Considering that 44.2% 
of the study patients were taking two or more breathing 
medications, monthly inhaler costs would likely be 
significantly higher than what most patients could afford. 
 
Ultimately, lack of access to breathing medications can lead 
to cost-related nonadherence and poor disease control. A 
common theme from patient interviews was history of using 
inhalers incorrectly to extend their duration of use. Two 
interviewees reported spreading out the doses of their 
inhalers to make them last longer when unable to obtain 
their breathing medications. Another interviewee admitted to 
using a family member’s or friend’s inhalers, which did not 
contain the correct medication for the patient’s diagnosis and 
therefore did not work properly to control his/her disease.   
 
All interviewees shared frequenting the ED and/or hospital 
more often prior to coming to the charitable pharmacy due to 
lack of breathing medication access. One interviewee 
admitted to going to the ED whenever his/her inhaler ran out 
so that the interviewee could get a new one because the ED 
was the only reliable access route for breathing medications.  
According to a study by Dalal et al. (2011), mean costs for 
COPD exacerbation ED visits in 2008 were $647, while mean 
costs for COPD exacerbation hospital admissions ranged from 
$7,242 to $44,909 depending on complexity.17 Unfortunately, 
the high cost associated with lung disease is not expected to 
decrease any time soon. According to researchers at the 
Centers for Disease Control and Prevention, national annual 
COPD medical costs are projected to increase from $32.1 
billion in 2010 to $49 billion by 2020.18 
 
While this study identified several important challenges 
facing underserved patients utilizing breathing medications, 
there are limitations to consider. One limitation is that the 
study data is from a “snapshot” three-month time period. It is 
possible that results could be different depending on the time 
of year studied, with seasonal variation accounting for 
differences in inhaler needs. For example, more patients 
could be filling inhalers during the spring due to seasonal 
allergies. However, the purpose of the study was to describe 
characteristics of the population that relies on a charitable 
pharmacy for breathing medications, and the study 
investigators did not feel that the overall characteristics of 
the population would significantly change. Three months was 
chosen versus a shorter period of time in order to capture 
patients who may have only been prescribed an “as-needed” 
or “rescue” medication, since the patient may not need to get 
a new inhaler every month if using the medication 
infrequently.   
 
Another limitation is that Phase I relies on a retrospective 
chart review, so the accuracy of the data is dependent on 
accurate record-keeping at the pharmacy. This study only 
accounts for breathing medications that were filled at the 
charitable pharmacy, so the 27.6% of patients who utilized 
resources outside of the charitable pharmacy had 
unaccounted for experiences regarding those breathing 
medications. Additionally, much of the data in the medical 
chart is patient-reported, including diagnoses, insurance 
status, and a portion of the information gathered from the 
medical record review. In regard to insurance status, it is 
possible that some uninsured patients were eligible for 
affordable income-based coverage and were unaware, which 
would overestimate the magnitude of the problem regarding 
access to breathing medications. It is also possible that if 
some patients had assistance in selecting their insurance 
plans, they may be able to better afford their breathing 
medications at a reasonable price.  However, the data 
presented in this study conveys the reality that in practice it 
may not always be possible to optimize each patient’s 
insurance plan prior to granting access to charitable 
pharmacy resources.     
 
The small sample size and selection of interviewees in Phase 
II is a limitation as well. Patients were selected based on their 
insurance status and are not a true representation of the 
entire population of patients filling breathing medications at 
the pharmacy. However, the purpose of Phase II was to share 
individual patient experiences regarding their respiratory 
health and medication access issues, so the research 
investigators focused on the quality of stories gathered. The 
patient interview data was used to support the quantitative 
data collected and personalize the issue of medication access 
in the underserved population. 
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Opportunities exist for further exploration into breathing 
medication access issues. Respiratory disease-related ED and 
hospital admission rates of patients at a charitable pharmacy 
could be compared to the general population or a population 
of similar low income status. In addition, respiratory disease-
related ED and hospital admission costs could be compared 
to the costs of breathing medications. As poor perception of 
respiratory health was a common theme among our 
interviewees, a future study could examine factors that 
contribute to health perception in uninsured or underinsured 
patients with respiratory disease. Therapeutic regimens could 
be analyzed for appropriateness based on current respiratory 
guidelines in uninsured or underinsured patients. In addition, 
pharmacist collaboration with prescriber offices in assisting 
with the selection of accessible breathing medications could 
be explored, as could partnerships with other members of 
the health care team to explore eligibility and optimization of 
a patient’s health plan selection. 
 
Conclusion 
Use of breathing medications was common in our population, 
and access remains a significant challenge regardless of 
insurance status or the available expertise and resources of a 
charitable pharmacy. The majority of breathing medications 
were prescribed for common diagnoses, but controller 
medications were seen in less than half of the patients. While 
this charitable pharmacy utilizes several routes to access 
breathing medications, over a quarter of the patients needed 
to seek outside resources to obtain therapy. Most commonly, 
the charitable pharmacy still had to purchase breathing 
medications. Collaborative, team-based efforts are needed to 
ensure that vulnerable populations can consistently access 
necessary breathing medications. 
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Table 1. Description of Medication Access Routes Commonly Utilized by a Charitable Pharmacy 
 
Access Route Description Patient Eligibility 
Criteria 
Pros Cons 
Bulk-
replenishment 
programs 
Drug 
manufacturer 
provides certain 
brand-name 
medication at no 
cost to patients 
who qualify 
Income and 
insurance 
criteria depend 
on particular 
program, but 
typically must be 
U.S. citizen and 
have no 
prescription 
insurance 
Brand-name 
medications 
readily available 
Eligibility 
requirements; 
supply limited to 
certain brand-
name drugs only 
Drug repository Unused drugs 
donated from 
nursing homes, 
long-term care 
facilities, and 
wholesalers 
Resident of Ohio 
and no 
prescription 
insurance or 
must be a 
patient of a 
nonprofit clinic 
Variety of drugs 
potentially 
available; may 
qualify even if 
has insurance if 
patient of 
nonprofit clinic 
Inconsistent drug 
supply based on 
donations 
Charitable 
distributor 
Organization 
provides 
donated 
medications 
from 
manufacturers 
and health 
systems 
At least 18 years-
old, ≤200% 
federal poverty 
level, and no 
prescription 
insurance 
Variety of drugs 
potentially 
available 
Must be 
uninsured to be 
eligible; 
inconsistent drug 
supply based on 
donations 
Purchase The Charitable 
Pharmacy of 
Central Ohio 
(CPCO) uses its 
own operating 
budget to 
purchase 
medication for 
patients who 
cannot access it 
from any 
alternative route 
Must be 
qualified as a 
patient of CPCO 
(i.e. >18 years, 
resident of 
Franklin county, 
and ≤200% 
federal poverty 
level and having 
difficulty 
affording 
prescriptions) 
Any patient of 
CPCO is eligible 
to have access to 
drugs purchased 
by CPCO 
CPCO operating 
budget is limited, 
so it can only 
provide 
relatively low-
cost drugs and is 
often route of 
last resort 
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Table 2. Demographic Data 
 
 Mean ± SD (range), or n (%) 
Age 57.9 ± 10.7 (21.7 – 83.6) 
Gender   
  Male 82 (45.3%) 
  Female 99 (54.7%) 
Race  
  Caucasian 69 (40.6%) 
  Black 90 (52.9%) 
  Other 11 (6.5%) 
Insurance status  
  Uninsured  84 (46.4%) 
  Medicare A & B 30 (16.6%) 
  Medicare A, B, & D 38 (21.0%) 
  Medicaid 12 (6.6%) 
  Private 9 (5.0%) 
  Other 8 (4.4%) 
Pulmonary diagnosis  
  Asthma 75 (41.4%) 
  COPD 65 (35.9%) 
  Asthma and COPD 24 (13.3%) 
  Unknown 11 (6.1%) 
  Other 6 (3.3%) 
 
 
 
 
 
Table 3. Examples of “As Needed” and “Controller” Breathing Medications 
 
As Needed: albuterol (ProAir®, Proventil®, Ventolin®), 
ipratropium/albuterol (Combivent®)*, levalbuterol 
(Xopenex®) 
Controller: aclidinium (Tudorza®), beclomethasone (Qvar®), 
budesonide (Pulmicort®), budesonide and formoterol 
(Symbicort®), fluticasone (Flovent®), fluticasone and 
salmeterol (Advair®), mometasone (Asmanex®), 
mometasone and formoterol (Dulera®), montelukast 
(Singulair®), roflumilast (Daliresp®), salmeterol (Serevent®), 
theophylline ER, tiotropium (Spiriva®) 
 
*Combivent ® may be used “as needed” or regularly as a “controller” medication.  It was categorized as an “as needed” 
breathing medication for study purposes. 
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Table 4. Patient Case Summaries 
 
Patient 1 Patient with history of smoking was diagnosed with asthma and chronic obstructive 
pulmonary disease (COPD) over twenty years ago during hospitalization for acute 
bronchitis.  Before coming to the Charitable Pharmacy of Central Ohio (CPCO), patient 
reported scraping money together to get whatever inhalers patient could afford, 
though patient always found a way to get long-acting anticholinergic inhaler and 
referred to it as “magic stuff.”  Patient reported having to make a decision between 
medication and food.  When asked how much patient could spend on breathing 
medications, patient reported $50 maximum per month.  Patient reported taking long-
acting anticholinergic inhaler differently than prescribed at times by skipping doses to 
make it last longer when CPCO was unable to provide this medication. 
 
Patient 2  Patient with history of childhood asthma also diagnosed with COPD.  Before coming to 
CPCO, patient reported purchasing breathing medications at the cheapest retail price 
patient could find.  When asked how much patient could spend on breathing 
medications, patient reported $20-$40 per month.  Patient reported that CPCO has had 
to call physician in the past to switch the brand of prescribed inhalers to inhaler more 
readily available through the pharmacy’s access routes.  Patient also reported CPCO 
requested nebulized medications for patient due to access issues. 
 
Patient 3 Patient with a strong family history of asthma was diagnosed as an adult.  Patient 
struggled to afford breathing medications and used family member’s or a friend’s 
inhalers which did not work well because the other inhalers were prescribed for COPD.  
Uncontrolled asthma greatly interfered with daily tasks and ability to perform job.  
Patient reported that CPCO had contacted physician to change one of patient’s inhalers 
due to uncontrolled asthma, and breathing was much better on the new regimen.  
When asked how much patient could spend on breathing medications per month, 
patient said patient would be unable to afford them because they are very expensive. 
 
Patient 4 Patient with history of smoking was diagnosed with COPD upon a routine physician visit 
due to shortness of breath.  Patient reported going without breathing medications 
often before coming to CPCO.  Patient went to emergency room if unable to tolerate 
shortness of breath.  Patient has tried to “spread out” doses of inhalers to make them 
last longer but reports they do not work as well when taken this way.  When asked how 
much patient could spend on breathing medications per month, patient responded that 
it wouldn’t be much at all. 
 
Patient 5 Patient diagnosed with asthma in teenage years and ended up in emergency room 
often due to losing job and insurance coverage.  Patient reported that over-the-counter 
inhalers did not work well and described life with asthma “confining” due to avoiding 
exposure to the outdoors due to exacerbations.  When asked how much patient could 
spend on breathing medications per month, patient reported $20, if that.  Before 
coming to CPCO, patient would go to emergency room if breathing was troublesome 
and use the inhaler received there.  Once inhaler ran out, patient would go back to the 
emergency room.  Patient reported going without prescribed inhaler a few times 
because CPCO could not access it and physician was not willing to substitute an 
alternative medication.  
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Appendix A: Patient Interview Questions 
 
o Pulmonary disease history: 
• I see that you are taking a breathing medication(s).  Please tell me why you were prescribed this medication. 
• Tell me about when you were first diagnosed with airway disease. 
• How has your breathing changed, if at all, since you were diagnosed? 
• Why do you think your breathing has gotten better/worse? 
• What is your life like with airway disease? 
o Payer situation: 
• How did you get your breathing medications before coming to the Charitable Pharmacy? 
• Why could you no longer get your breathing medications in that way? 
• If insurance: how do you feel about having difficulty affording your medications even though you have insurance?  
• If no insurance: do you feel that getting your breathing medications would be different if you had insurance? 
• How much would you currently be able to spend per month on breathing medications?  
o Perception of pulmonary health: 
• How often did you go without breathing medications before coming to the Charitable Pharmacy?  If often, why? 
• How often were you hospitalized due to breathing issues prior to coming to the Charitable Pharmacy? 
• Since coming to Charitable Pharmacy, how often do you go without your breathing medications?  If often, why? 
• How often have you been hospitalized due to breathing issues since coming to the Charitable Pharmacy? 
• Do you feel like your breathing is better or worse when you are able to get your breathing medication? 
o Modifications to breathing regimen: 
• To your knowledge, has the Charitable Pharmacy ever had to ask your doctor to change your breathing medication?  How 
do you feel about this? 
• Have you ever tried to make your breathing medication last longer so you would not run out?  If so, tell us which 
medication and how you took it. 
• Do you take your breathing medications every day or only as needed?  Why do you take them this way? 
o Ongoing access: 
• If you got new prescriptions, where would you go first to get your medications? 
• What would you do if your breathing medications were not working? 
• Where would you go to ask a question about your breathing medications?  Who would you ask?  
• Are you still getting your breathing medication from the Charitable Pharmacy?  If not, why? 
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